Ausdal Financial Partners’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Ausdal Financial Partners’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-1,415	Closed	-$71K	–	787
2015 Q4	$71K	Buy	+1,415	New	+$69.9K	0.04%	373

Other funds holding PBE

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TAM

Trillium Asset Management Boston, Massachusetts $3.01B AUM 19.96% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

TCM

Traynor Capital Management Malvern, Pennsylvania $1.7B AUM 39.15% 1-Year Est. Return

HBT

Hills Bank & Trust North Liberty, Iowa $2.07B AUM 13.46% 1-Year Est. Return

CAS

Cue Advisory Services Phoenix, Arizona $167M AUM 18.62% 1-Year Est. Return

Ausdal Financial Partners's PBE Position: Q1 2016 in Review

Ausdal Financial Partners sold out of Invesco Biotechnology & Genome ETF (PBE) in Q1 2016, closing a stake of 1,415 shares — an estimated $71K sold.

Ausdal Financial Partners first reported a position in PBE in Q4 2015 and held it in 1 quarter. The position peaked at $71K in Q4 2015. 71 funds tracked by Wall St. Rank hold PBE as of Q1 2016.

Ausdal Financial Partners reported no remaining Invesco Biotechnology & Genome ETF position as of Q1 2016 after selling out during the quarter.
Ausdal Financial Partners sold 1,415 Invesco Biotechnology & Genome ETF shares in Q1 2016, an estimated $71K.
Ausdal Financial Partners first reported a position in Invesco Biotechnology & Genome ETF in Q4 2015 and held it in 1 quarter.
Ausdal Financial Partners's Invesco Biotechnology & Genome ETF position peaked at $71K in Q4 2015.
71 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2016.

Based on Ausdal Financial Partners's 13F filing for Q1 2016, filed 5 May 2016.